AM, B., Y, L., JS, G., LM, M., C, G., S, N. S., . . . MA, J. (2026). A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML. Blood advances. https://doi.org/10.1182/bloodadvances.2026019848
Chicago Style (17th ed.) CitationAM, Brunner, et al. "A Phase Ib/II Study of Ceralasertib, a Selective Inhibitor of ATR, in Patients with Relapsed or Refractory MDS and CMML." Blood Advances 2026. https://doi.org/10.1182/bloodadvances.2026019848.
MLA (9th ed.) CitationAM, Brunner, et al. "A Phase Ib/II Study of Ceralasertib, a Selective Inhibitor of ATR, in Patients with Relapsed or Refractory MDS and CMML." Blood Advances, 2026, https://doi.org/10.1182/bloodadvances.2026019848.
Warning: These citations may not always be 100% accurate.
